APROS-v9.2 açık kaynaklı hücresel işletim sistemi ve yaşlanma karşıtı kombinatoryal matris

APROS-V9.5 – Adaptive Performance and Recursive Operating System (Defensive Publication / Prior Art) Published by: Muzaffer Enes Yünlü DOI: 10.5281/zenodo.19428077 License: CC BY-NC-SA 4.0 Legal status: Publicly available technical document – constitutes prior art under patent law --- What is this document? APROS (Adaptive Performance and Recursive Operating System) is a biological operating system that coordinates epigenetic reset, metabolic repair, immune modulation, and oxidative stress management in human cells in real time. Original hypothesis: Epigenetic reset (F2) should NOT be applied at fixed intervals but automatically triggered when a dynamic threshold function (Φ_trigger > Γ) based on 18 biomarkers is satisfied. This hypothesis is not found in the literature and is unique to APROS-V9.5. Purpose: To prevent others from patenting this system and keep it in the public domain. --- Target Patient Population · Human (Homo sapiens) · Age >60 or diagnosed with chronic disease (cancer, neurodegeneration, metabolic syndrome) · Application: Ex vivo (PBMC, T cells, MSC) or in vivo (IV, subcutaneous, intrathecal) --- I. Combinatorial Targeting Matrix Positive Targeting Ligands (7 tissues × 7 ligands = 49 ligands) Tissue Ligands Neural NCAM, TrkB, mGluR5, Synaptotagmin-1, N-Cadherin, L1CAM, GLAST Muscle Integrin α7β1, Dystroglycan, GLUT4, IGF-1R, Cav3, M-cadherin, Myomaker Metabolic ASGPR, GLP-1R, LDLR, Insulin Receptor, GCGR, AdipoR1, GLUT2 Immune CD3, CD14, Siglec-1, CD19, CD4, CD8, CD206 Barrier/Other ACE2, VEGFR2, Megalin, E-Cadherin, Podocalyxin, Claudin-5, ZO-1 Negative Selection Ligands (8 total, with SEQ ID NO: 1-6) Off-Target Tissue Negative Ligand Non-liver GalNAc-ASGPR antagonist Non-muscle Myomaker inhibitor peptide (SEQ ID NO: 1) Non-neural L1CAM-blocking nanobody (SEQ ID NO: 6) Non-endothelial Claudin-5 antagonist peptide (SEQ ID NO: 2) Non-immune CD47-activating peptide (SEQ ID NO: 3) Non-tumor Phosphatidylserine masker Non-pancreatic β GLP-1R blocking peptide (SEQ ID NO: 4) Non-cardiomyocyte Cav3 antagonist (SEQ ID NO: 5) Total addressing code: 23,296 combinations --- II. Dynamic Threshold Function – 18 Biomarkers Category Biomarkers Measurement Method Senescence p16, p21, p53, Ki67 qPCR or ELISA DNA damage γH2AX, 8-OHdG, Telomere length Fluorescent antibody / ELISA / qPCR Oxidative stress ROS (H₂O₂), RNS, NAD⁺/NADH Amplex Red / DAF-FM DA / cycling kit Metabolic ATP/ADP, p-mTOR, p-AMPK, GLUT4 Luminometric / phospho-antibody / qPCR Inflammation IL-6, TNF-α, IL-10 ELISA Epigenetic 5mC/5hmC ratio HPLC-MS Dynamic Threshold Function: Φ = Σ w_n · σ((B_n - θ_n)/α_n) · (1 + β_n · (dB_n/dt)/(dB_n/dt)_max) Trigger condition: IF (Φ > Γ) AND (min((dB_n/dt)/α_n) > -Δ) THEN initiate Parameter ranges: Parameter Range Default θ_n 0.001-1000 Determined at F0 α_n 0.1-10.0 1.0 β_n 0-1 0.3 w_n 0-1 1/18 Γ 0-1 0.6 Δ 0-1 0.1 θ_n determination method (at F0): θ_n = healthy control population mean + 2 × standard deviation --- III. Intervention Phases (F1–F5) and Active Agents Phase Agent Dose Carrier F1 Navitoclax (ABT-263) 25 mg/kg Galactose-LNP F1 (alt) Nutlin-3a 10 mg/kg Galactose-LNP F2 OSKM modRNA 0.5 mg/kg LNP F2 (alt) OSK modRNA 0.5 mg/kg LNP F3 NAD⁺ 200 mg/kg LNP F3 (alt) Nicotinamide 100 mg/kg Oral/LNP F4 Urolithin A 500 mg Oral/LNP F4 (alt) FGF21 1 mg/kg LNP F5 IL-10 modRNA 0.3 mg/kg LNP F5 (alt) Low-dose IL-2 1.5 million IU Injection LNP Formulation (molar ratio): · DSPC: 25% · Cholesterol: 40% · DOPE: 25% · PEG: 10% · Particle size: 80 ± 20 nm (DLS) · PDI: < 0.2 · Zeta potential: -10 ± 5 mV modRNA Protocol: · Structure (5' → 3'): [CleanCap AG] – [α-globin 5' UTR] – [OSKM/OSK] – [α-globin 3' UTR] – [polyA(120)] · Nucleotides: ATP, CTP, GTP, N1-methyl-pseudo-UTP (fully substituted) · RNA polymerase: T7 · Purification: LiCl precipitation or HPLC Phase Sequence: ALL 5! = 120 permutations are prior art Duration and Cycle: · Each phase: 1-336 hours (1-hour increments) · Washout: 24 hours (mandatory) · Rest: 48 / 72 / 96 / 120 / 144 / 168 hours · Number of cycles: 1-10 (integer) --- IV. Yamanaka Combinations (27 Regimens) Type Combinations 7-factor OSKMLNE 6-factor OSKMLN 5-factor OSKMN, OSKML, OSKME 4-factor OSKM, OSKL, OSKN, OSKE, OSMN, OKMN, SKMN, OSLN 3-factor OSK, OKM, SKM, OSL, OKL, OML, SKL, SML, KML 2-factor OS, OK, OM, SK, SM, KM 1-factor O, S, K, M Duration options: 24, 48, 72, 96 hours --- V. Kill-Switch (4 Layers, 15 Subsets) # Mechanism Trigger Reference 1 FKBP12(F36V) degron Time > 24 hours Nabet 2018 2 Tissue miRNA (miR-122/-1/-124/-142) Wrong tissue miRBase 3 dCAS9-KRAB Unwanted expression Gilbert 2013 4 Intracellular sensor p53 > λ1, ROS > λ2, ATP < λ3 Section III Combinations: 1, 2, 3, 4 or any subset thereof (15 total combinations) --- VI. F0: Mandatory Diagnostic Mapping 1. Blood or tissue biopsy 2. 18 biomarker measurement 3. RNA-seq (transcriptome) 4. LC-MS/MS (proteome) 5. NMR/LC-MS (metabolome) 6. Determine θ_n and w_n Duration: 24-72 hours --- VII. Learning System w_n^(k+1) = w_n^(k) + η · (target_B_n · actual_B_n) · actual_B_n η = 0.1 (learning rate) Implementation: Computed externally in Python, MATLAB, or Excel. --- What is covered as prior art? · Original hypothesis (on-demand reset) · 49 positive + 8 negative ligands (with SEQ ID NO: 1-6) · 23,296 addressing combinations · 18 biomarkers and dynamic threshold function · ALL 120 phase permutations · 27 Yamanaka combinations · 4-layer kill-switch (15 subsets) · LNP formulation and modRNA protocol · Learning system (η = 0.1) · Obvious variations (under KSR v. Teleflex, 2007): · ±20% dose changes · Routine parameter optimization · Substitution with similar ligands --- What is NOT covered? · Chemical synthesis of ligands (standard literature) · Functional validation in specific cell lines · Any efficacy claims (only "how to use" is defined) --- Who is this for? · Patent offices (prior art search) · Molecular biologists, bioengineers, epigenetic researchers · Cell therapy and gene therapy companies · Open science advocates --- How to cite? Yünlü, M. E. (2026). APROS-V9.5: Defensive Publication and Prior Art Document – Adaptive Performance and Recursive Operating System. Zenodo. https://doi.org/10.5281/zenodo.19428077 (April 15, 2026) --- Not / Note: Bu dokümanda tanımlanmayan hiçbir şey için prior art iddiasında bulunulmaz. No prior art is claimed for anything not explicitly defined in this document.